Opus Genetics has reported early findings from its ongoing Phase I/II clinical trial of the OPGx-BEST1 gene therapy to treat ...
Medtech companies like BlueWind or Medtronic are increasingly investing in neuromodulation to treat urgency urinary ...
The FENhance 1 and 2 trials involved 1,497 adults with RMS. Credit: New Africa / Shutterstock.com. Roche has reported that the pivotal Phase III FENhance 1 trial of its investigational Bruton’s ...
MSD has announced findings from the pivotal Phase III LITESPARK-022 trial, assessing the Keytruda-Welireg combination as adjuvant therapy for patients with clear cell RCC after nephrectomy.
Faster and more cost-effective trials support early-stage research in China driving the country's drug discovery engine.
Mahzi Therapeutics has dosed the first patient in its Phase I/II UNITE study assessing MZ-1866, an investigational gene ...
Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010.
In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema ...
Novo Nordisk and United Laboratories’ jointly developed triple G drug has achieved a 19.7% weight loss in a Phase II trial in ...
Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to ...
C4 Therapeutics has dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, combined with dexamethasone for patients with RRMM.
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results